It is important to Tacrolimus mouse present both treatment options to the family in a balanced way, taking into account not only the SEGA, but the specific individual with the variance of TSC associated comorbidities. Currently there is no evidence for the superiority of one treatment over the other, unless there are specific factors that favor one treatment over another as discussed previously. SEGA patients should be discussed in a multidisciplinary team including neurologists/oncologists and neurosurgeons to thoroughly weigh pros and cons of the respective treatment modality before

finalizing an individualized treatment recommendation. The 2012 International TSC Clinical Consensus Conference was sponsored and organized by the Tuberous Sclerosis Alliance. The conference was supported by generous sponsors who donated funds to the Tuberous Sclerosis Alliance without playing a role in the planning or having a presence at the conference or any influence on the resulting recommendations: the Rothberg Institute for Childhood Diseases, Novartis Pharmaceuticals, Sandra and Brian O’Brien, and Questcor Pharmaceuticals. “
“In the review article “Childhood onset of limb-girdle muscular dystrophy” by Rosales et al. in the January 2012 issue, Roula al-Dahhak was omitted as a co-primary author. The corrected citation appears below. Rosales XQ, al-Dahhak R, Tsao C-Y. Childhood onset of limb-girdle

muscular dystrophy. Pediatric Neurology 2012; 46:13–23. “
“In the article “Marked Improvement in Segawa Syndrome After l-dopa Alisertib price and Selegiline Treatment” by Yosunkaya et al. in the May 2010 issue (2010;42:348-35025-28; doi: 10.1016/j.pediatrneurol.2010.01.008), an acknowledgment was omitted. The acknowledgment should have stated “This work was supported by Istanbul University research fund under project number UDP-3595/09042009.” The authors regret the error. “
“In the article “APOE Gene ε Polymorphism Does Not Determine Predisposition to Ischemic Stroke in Children”

by Balcerzyk et al. in the July 2010 issue (2010;43:25-28; doi: 10.1016/j.pediatrneurol.2010.02.016), the author line was incorrect. The corrected author line and affiliations appear below. The authors regret the errors. Anna Balcerzyk, PhD*, Iwona Żak, PhD*, Paweł Niemiec, www.selleck.co.jp/products/atezolizumab.html PhD*, Ilona Kopyta, PhD†, Ewa Emich-Widera, PhD†, Tomasz Iwanicki, MSc*, Ewa Pilarska, PhD‡, Karolina Pienczk-Ręcławowicz, MD‡, Marek Kacinski, PhD,§ Jerzy Wendorff, PhD,¶ Joanna Jachowicz-Jeszka, PhD From the *Department of Biochemistry and Medical Genetics, School of Health Care, Medical University of Silesia, Katowice, Poland; †Department of Neuropediatrics, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland; ‡Department of Developmental Neurology, Medical University of Gdansk, Gdansk, Poland; §Department of Pediatric and Adolescent Neurology, Jagiellonian University Medical College, Kraków, Poland; and ¶Department of Neurology, Polish Mother’s Memorial Hospital-Research Institute, Łódź, Poland.